What is appropriate neoadjuvant/adjuvant androgen deprivation for high-risk/locally advanced prostate cancer?

被引：3
|
作者：
Namiki, Mikio [1 ]
Konaka, Hiroyuki [1 ]
机构：
[1] Kanazawa Univ, Grad Sch Med Sci, Dept Integrat Canc Therapy & Urol, Kanazawa, Ishikawa 9208640, Japan
来源：
ASIAN JOURNAL OF ANDROLOGY | 2011年 / 13卷 / 04期
关键词：
RADIATION-THERAPY; RADICAL PROSTATECTOMY; BRACHYTHERAPY; DURATION; TRIAL;
D O I：
10.1038/aja.2011.74
中图分类号：
R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：624 / 625
页数：2
相关论文
共 50 条
  • [21] Adjuvant Radiation, Androgen Deprivation, and Docetaxel for High-Risk Prostate Cancer Postprostatectomy: Results of RTOG 0621
    Hurwitz, M. D.
    Zhang, Q.
    Sartor, O.
    Xiao, Y.
    Shayegan, B.
    Sperduto, P. W.
    Badiozamani, K. R.
    Lawton, C. A.
    Horwitz, E. M.
    Michalski, J. M.
    Roof, K.
    Beyer, D. C.
    George, A.
    Sandler, H. M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S2 - S2
  • [22] Optimal duration of neoadjuvant androgen deprivation therapy for prostate volume reduction in locally advanced prostate cancer radiotherapy
    Bagri, P. K.
    Samdariya, S.
    Pareek, P.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 75 - 75
  • [23] A Prospective Trial of Aggressive Therapy Consisting of Neoadjuvant Chemotherapy and Androgen Deprivation Followed by Prostatectomy and Adjuvant Radiation in High/Very High-Risk Prostate Cancer
    Kwok, Y.
    Mirkheshti, N.
    Naslund, M.
    Hussain, A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S77 - S77
  • [24] High Gleason score predicts poor pathologic outcome after neoadjuvant androgen deprivation for locally advanced prostate cancer
    Srougi, M
    Kauffmann, JR
    Nesrallah, A
    Leite, KRM
    [J]. MOLECULAR UROLOGY, 1998, 2 (03) : 195 - 199
  • [25] Locally advanced prostate cancer treated with radiotherapy and androgen deprivation
    Roger Kirby
    [J]. Nature Clinical Practice Urology, 2005, 2 : 304 - 308
  • [26] Locally advanced prostate cancer treated with radiotherapy and androgen deprivation
    Kirby, R
    [J]. NATURE CLINICAL PRACTICE UROLOGY, 2005, 2 (06): : 304 - 308
  • [27] Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy
    Qu, Feng
    Gu, Yue
    Xue, Mengxia
    He, Mingzhe
    Zhou, Fang
    Wang, Guangji
    Peng, Ying
    [J]. PROSTATE, 2021, 81 (09): : 560 - 571
  • [28] Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy
    Beltran, Himisha
    Wyatt, Alexander W.
    Chedgy, Edmund C.
    Donoghue, Adam
    Annala, Matti
    Warner, Evan W.
    Beja, Kevin
    Sigouros, Michael
    Mo, Fan
    Fazli, Ladan
    Collins, Colin C.
    Eastham, James
    Morris, Michael
    Taplin, Mary-Ellen
    Sboner, Andrea
    Halabi, Susan
    Gleave, Martin E.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6802 - 6811
  • [29] Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer
    Lamb, DS
    Denham, JW
    Mameghan, H
    Joseph, D
    Turner, S
    Matthews, J
    Franklin, I
    Atkinson, C
    North, J
    Poulsen, M
    Kovacev, O
    Robertson, R
    Francis, L
    Christie, D
    Spry, NA
    Tai, KH
    Wynne, C
    Duchesne, G
    [J]. RADIOTHERAPY AND ONCOLOGY, 2003, 68 (03) : 255 - 267
  • [30] Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer
    Ohashi, Toshio
    Yorozu, Atsunori
    Saito, Shiro
    Momma, Tetsuo
    Nishiyama, Toru
    Yamashita, Shoji
    Shiraishi, Yutaka
    Shigematsu, Naoyuki
    [J]. RADIATION ONCOLOGY, 2014, 9
12345